首页 | 本学科首页   官方微博 | 高级检索  
     


Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
Authors:Teresa A Simon  Johan Askling  Diane Lacaille  Jarrod Franklin  Frederick Wolfe  Allison Covucci  Samy Suissa  Marc C Hochberg  the Abatacept Epidemiology Study Group
Affiliation:1.Global Health Economics and Outcomes Research, Bristol-Myers Squibb,Lawrenceville,USA;2.Department of Medicine, Clinical Epidemiology Unit,Karolinska University Hospital Solna, Rheumatology Unit d2:01, Karolinska University Hospital Solna,Stockholm,Sweden;3.Division of Rheumatology, Department of Medicine, Arthritis Research Centre of Canada,University of British Columbia,Vancouver,Canada;4.Arc Epidemiology Unit, School of Medicine,University of Manchester, Stopford Building,Manchester,UK;5.Medical School,University of Sheffield,Sheffield,UK;6.Department of Internal Medicine, National Data Bank for Rheumatic Diseases,Arthritis Research Foundation and University of Kansas,Wichita,USA;7.Global Biostatistics,Hopewell,USA;8.Center for Clinical Epidemiology, Lady Davis Research Institute,Jewish General Hospital,Montreal,Canada;9.Departments of Medicine and Epidemiology and Preventive Medicine,University of Maryland School of Medicine,Baltimore,USA
Abstract:

Introduction  

Patients with rheumatoid arthritis (RA) have an increased risk of infection and this risk appears to be higher with anti-TNF (tumor necrosis factor) agents. We pooled data from the cumulative abatacept RA clinical development program, both double-blind and open-label periods, to estimate the incidence rates (IRs) of infections requiring hospitalization including pneumonia and opportunistic infections, in comparison with RA patients treated with non-biologic disease-modifying antirheumatic drugs (DMARDs) from several reference cohorts.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号